100 related articles for article (PubMed ID: 25001659)
1. Melanoma and IFN alpha: potential adjuvant therapy.
Bottoni U; Clerico R; Paolino G; Corsetti P; Ambrifi M; Brachini A; Richetta A; Nisticò S; Pranteda G; Calvieri S
J Biol Regul Homeost Agents; 2014; 28(2):271-9. PubMed ID: 25001659
[TBL] [Abstract][Full Text] [Related]
2. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
3. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
Fujisawa Y; Otsuka F;
Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797
[TBL] [Abstract][Full Text] [Related]
4. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
5. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
6. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
Mocellin S; Pasquali S; Rossi CR; Nitti D
J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
9. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in young women with cutaneous melanoma.
Burton AL; Egger ME; Quillo AR; Stromberg AJ; Hagendoorn L; Scoggins CR; Martin RC; McMasters KM; Callender GG
Am J Surg; 2014 Jan; 207(1):102-8. PubMed ID: 24330977
[TBL] [Abstract][Full Text] [Related]
11. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
12. Who benefits most from adjuvant interferon treatment for melanoma?
Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
14. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
Eggermont AM; Spatz A; Lazar V; Robert C
Curr Opin Oncol; 2012 Mar; 24(2):137-40. PubMed ID: 22234255
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.
Ascierto PA; Gogas HJ; Grob JJ; Algarra SM; Mohr P; Hansson J; Hauschild A
Crit Rev Oncol Hematol; 2013 Feb; 85(2):149-61. PubMed ID: 22874771
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant interferon-alpha for melanoma revisited: news from old and new studies.
Punt CJ; Eggermont AM
Ann Oncol; 2001 Dec; 12(12):1663-6. PubMed ID: 11843241
[TBL] [Abstract][Full Text] [Related]
18. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes.
Zogakis TG; Essner R; Wang HJ; Foshag LJ; Morton DL
Ann Surg Oncol; 2007 May; 14(5):1604-11. PubMed ID: 17333418
[TBL] [Abstract][Full Text] [Related]
19. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
20. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]